Ares Financial Consulting’s Madrigal Pharmaceuticals MDGL Stock Holding History
Bought
Maintained
Sold
Other funds holding MDGL
BBA
Ares Financial Consulting's MDGL Position: Q3 2026 in Review
Ares Financial Consulting held its Madrigal Pharmaceuticals (MDGL) position steady in Q3 2026 at 5 shares worth $2.52K. The position accounts for ﹤0.01% of the portfolio, ranked #835.
Ares Financial Consulting first reported a position in MDGL in Q2 2026 and has held it in 2 quarters since. The position peaked at $2.68K in Q2 2026. 434 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.
- Ares Financial Consulting held 5 shares of Madrigal Pharmaceuticals worth $2.52K as of Q3 2026.
- Ares Financial Consulting left its Madrigal Pharmaceuticals share count unchanged in Q3 2026.
- Madrigal Pharmaceuticals made up ﹤0.01% of Ares Financial Consulting's portfolio in Q3 2026, its #835 holding.
- Ares Financial Consulting first reported a position in Madrigal Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
- Ares Financial Consulting's Madrigal Pharmaceuticals position peaked at $2.68K in Q2 2026.
- 434 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.
Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.